Endoscopic submucosal dissection (ESD) compared with gastrectomy for treatment of early gastric neoplasia: a retrospective cohort study

This study aims to compare perioperative outcomes and oncological clearance of endoscopic submucosal dissection (ESD) versus gastrectomy for treatment of early gastric cancer (EGC).

This is a retrospective cohort study including all cases of EGC or severe dysplasia treated at a university-affiliated hospital from 1993 to 2010. Preoperative endoscopic ultrasound and image-enhanced endoscopy were employed to determine depth of invasion. Clinical outcomes including baseline demographics, pathology, postoperative complication, and hospital stay, as well as 3-year survival were compared.

From 1993 to 2010, 114 patients with severe dysplasia or EGC were treated: 40 of them received gastrectomy, while 74 received ESD. There was no difference in age, gender, comorbidity or American Society of Anesthesiologists grade between the two groups. Of patients in the gastrectomy group, 92.5 % presented with symptoms as compared with 27.0 % of those treated by ESD (p < 0.001). More patients in the ESD group had atrophic gastritis (31.1 vs 10 %; p = 0.009) and intestinal metaplasia (68.9 vs 55.0 %; p = 0.04). Patients treated by gastrectomy sustained longer operative time [265 (150–360) min] when compared with ESD [89.6 (45–360) min; p < 0.001]. They also had longer median hospital stay [9.9 (6–26) days vs 3.0 (2–10) days; p < 0.001]. There was no perioperative mortality, but the overall complication rate was significantly higher in the gastrectomy group. The 3-year survival rate was 94.6 % for ESD and 89.7 % for gastrectomy group (log-rank test, p = 0.44).

ESD achieved similar oncological outcomes when compared with radical gastrectomy for treatment of EGC. Patients receiving ESD had better perioperative outcomes in terms of operative time, complication rate, and hospital stay.